Greener by Eutectic: Deep Eutectic Solvent Routes to Anticancer 2-Arylbenzothiazoles

  • Unique Paper ID: 211026
  • Volume: 13
  • Issue: 6
  • PageNo: 3009-3020
  • Abstract:
  • The pharmaceutical industry generates more waste per kilogram of product than any other chemical sector — E factors of 25 to 100 against 0.1 for oil refining — and the largest single contributor is solvent. Any synthetic route that eliminates volatile organic solvent therefore improves the environmental profile of a target molecule more than almost any other change available to the medicinal chemist. The 2-arylbenzothiazoles are a particularly worthwhile target for that treatment. Since the identification of 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and its fluorinated analogue 5F 203, the scaffold has produced a clinical candidate, the lysylamide prodrug Phortress, and a mechanism unlike that of any conventional cytotoxic: selective uptake by sensitive tumour cells, induction of cytochrome P450 1A1, bioactivation to reactive electrophiles, and formation of DNA adducts and single-strand breaks in sensitive but not resistant lines. The Phase 1 trial of Phortress did not establish a recommended dose and the programme stopped, but the pharmacophore remains actively worked, now principally through hybridisation and structure-based design against kinase and tubulin targets. The classical route to the ring — cyclocondensation of 2-aminothiophenol with an aromatic aldehyde — is simple, high-yielding and almost ideally suited to a solvent that can also act as catalyst and be recovered. Deep eutectic solvents, of which the 1:2 choline chloride–urea eutectic “reline” is the archetype, are exactly such media: cheap, biodegradable, negligibly volatile, formed by simply mixing two solids, and recoverable by aqueous precipitation of the product. This review assembles the pharmacology and structure–activity relationships of the 2-arylbenzothiazole series, sets out the green-chemistry case quantitatively, compares the reported green routes to the ring, examines deep eutectic solvents as reaction media and catalysts, and sets out what a credible DES-based synthesis with anticancer and docking evaluation would have to demonstrate.

Copyright & License

Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BibTeX

@article{211026,
        author = {Pragati Yadav and Swarup J Chatterjee},
        title = {Greener by Eutectic: Deep Eutectic Solvent Routes to Anticancer 2-Arylbenzothiazoles},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {6},
        pages = {3009-3020},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=211026},
        abstract = {The pharmaceutical industry generates more waste per kilogram of product than any other chemical sector — E factors of 25 to 100 against 0.1 for oil refining — and the largest single contributor is solvent. Any synthetic route that eliminates volatile organic solvent therefore improves the environmental profile of a target molecule more than almost any other change available to the medicinal chemist. The 2-arylbenzothiazoles are a particularly worthwhile target for that treatment. Since the identification of 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and its fluorinated analogue 5F 203, the scaffold has produced a clinical candidate, the lysylamide prodrug Phortress, and a mechanism unlike that of any conventional cytotoxic: selective uptake by sensitive tumour cells, induction of cytochrome P450 1A1, bioactivation to reactive electrophiles, and formation of DNA adducts and single-strand breaks in sensitive but not resistant lines. The Phase 1 trial of Phortress did not establish a recommended dose and the programme stopped, but the pharmacophore remains actively worked, now principally through hybridisation and structure-based design against kinase and tubulin targets. The classical route to the ring — cyclocondensation of 2-aminothiophenol with an aromatic aldehyde — is simple, high-yielding and almost ideally suited to a solvent that can also act as catalyst and be recovered. Deep eutectic solvents, of which the 1:2 choline chloride–urea eutectic “reline” is the archetype, are exactly such media: cheap, biodegradable, negligibly volatile, formed by simply mixing two solids, and recoverable by aqueous precipitation of the product. This review assembles the pharmacology and structure–activity relationships of the 2-arylbenzothiazole series, sets out the green-chemistry case quantitatively, compares the reported green routes to the ring, examines deep eutectic solvents as reaction media and catalysts, and sets out what a credible DES-based synthesis with anticancer and docking evaluation would have to demonstrate.},
        keywords = {2-Arylbenzothiazole; deep eutectic solvent; reline; green chemistry; E factor; anticancer; molecular docking; structure–activity relationship},
        month = {November},
        }

Cite This Article

Yadav, P., & Chatterjee, S. J. (2026). Greener by Eutectic: Deep Eutectic Solvent Routes to Anticancer 2-Arylbenzothiazoles. International Journal of Innovative Research in Technology (IJIRT), 13(6), 3009–3020.

Related Articles